Can Fite BioPharma Ltd (CANF)

[midastouch017]

Intracoastal Capital, Llc cuts stake in CANF / Can-Fite Biopharma Ltd.

https://fintel.io/news/intracoastal-capital-llc-cuts-stake-in-canf-can-fite-biopharma-ltd-0.2596377703529189
Fintel Staff

February 11, 2022

US:CANF
Intracoastal Capital, Llc cuts stake in CANF / Can-Fite Biopharma Ltd.
Intracoastal Capital, Llc has filed a 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 39,495,437 shares of Can-Fite Biopharma Ltd. (CANF). This represents 4.99 percent ownership of the company. In their previous filing dated January 29, 2021, the investor reported owning 32,911,650 shares and 6.60 percent of the company, indicating an increase in shares of 20.00 percent and a decrease in total ownership of 24.39 percent. The investor has filed 5 13D or G filings since April 11, 2019.

Top holders of Can-Fite Biopharma Ltd. sourced from 13F and NPORT filings include:

• Armistice Capital, Llc with 875,000 shares (0.11% ownership)

• Morgan Stanley with 196,675 shares (0.02% ownership)

• Cetera Advisor Networks LLC with 130,776 shares (0.02% ownership)

• Renaissance Technologies Llc with 93,405 shares (0.01% ownership)

• Fifth Third Bancorp with 30,000 shares (0.00% ownership)

• Acadian Asset Management Llc with 28,601 shares (0.00% ownership)

• Stifel Financial Corp with 12,000 shares (0.00% ownership)

• National Bank Of Canada /fi/ with 6,000 shares (0.00% ownership)

• Citigroup Inc with 5,535 shares (0.00% ownership)

• Wells Fargo & Company/mn with 1,500 shares (0.00% ownership)

Institutional sentiment is bullish.

There are 15 funds or institutions reporting positions in Can-Fite Biopharma Ltd.. This represents an increase of 2 owner(s) and 15.38 percent in the last three months. Average portfolio weight dedicated to Can-Fite Biopharma Ltd. is 0.0016 percent, an increase of 310.2301 percent in the last three months. Total shares owned by institutions increased in the last three months by 227.13 percent to 1,467,977 shares.